{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:46:42Z","timestamp":1787701602655,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40119-024-00390-5","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:06:58Z","timestamp":1730891218000},"page":"663-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expert Opinion on the Role of Sacubitril\/Valsartan in the Management of Hypertension in India"],"prefix":"10.1007","volume":"13","author":[{"given":"Uday M.","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumitra","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Govindan","family":"Unni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P. S.","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantanu","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv D.","family":"Karnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupen N.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh S.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Krishna","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya Kanti","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saujatya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashfaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Vishnu","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Manjappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujal","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimalraj Bogana","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"6","key":"390_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018912.","journal-title":"Circulation"},{"key":"390_CR2","unstructured":"The India state-level disease burden initiative\u2014Public Health Foundation of India. 2018. https:\/\/phfi.org\/the-work\/research\/the-india-state-level-disease-burden-initiative\/. Accessed 29 Feb 2024."},{"key":"390_CR3","unstructured":"National Family Health Survey (Nfhs-5) 2019\u201321.pdf. https:\/\/dhsprogram.com\/pubs\/pdf\/FR375\/FR375.pdf. Accessed 29 Feb 2024."},{"key":"390_CR4","unstructured":"Hypertension control rate in India: systematic review and meta-analysis of population-level non-interventional studies, 2001\u20132022. Lancet Regional Health Southeast Asia. https:\/\/www.thelancet.com\/journals\/lansea\/article\/PIIS2772-3682(22)00130-5\/fulltext. Accessed 29 Feb 2024."},{"issue":"7","key":"390_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","volume":"11","author":"RM Anjana","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474\u201389. https:\/\/doi.org\/10.1016\/S2213-8587(23)00119-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"390_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/HJH.0000000000000146","volume":"32","author":"R Anchala","year":"2014","unstructured":"Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32(6):1170\u20137. https:\/\/doi.org\/10.1097\/HJH.0000000000000146.","journal-title":"J Hypertens"},{"issue":"5","key":"390_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41440-022-00872-w","volume":"45","author":"M Ohishi","year":"2022","unstructured":"Ohishi M. Sacubitril\/valsartan\u2014a new weapon for fighting the hypertension paradox. Hypertens Res. 2022;45(5):915\u20136. https:\/\/doi.org\/10.1038\/s41440-022-00872-w.","journal-title":"Hypertens Res"},{"key":"390_CR8","unstructured":"Entresto (sacubitril\/valsartan) [prescribing information].pdf. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/entresto.pdf. Accessed 29 Feb 2024."},{"issue":"7","key":"390_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41440-022-00941-0","volume":"45","author":"S Hoshide","year":"2022","unstructured":"Hoshide S, Mogi M, Kario K. Current status of hypertension and treatment in Asia. Hypertens Res. 2022;45(7):1095\u20136. https:\/\/doi.org\/10.1038\/s41440-022-00941-0.","journal-title":"Hypertens Res"},{"key":"390_CR10","unstructured":"The world\u2019s first published expert consensus on ARNI treatment for hypertension. American College of Cardiology. Accessed 29 Feb 2024."},{"key":"390_CR11","doi-asserted-by":"publisher","unstructured":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012. Accessed 29 Feb 2024.","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"390_CR12","unstructured":"2023_esh_guidelines_for_the_management_of_arterial.271_0.pdf. https:\/\/www.portailvasculaire.fr\/sites\/default\/files\/docs\/2023_esh_guidelines_for_the_management_of_arterial.271_0.pdf. Accessed 29 Feb 2024."},{"key":"390_CR13","doi-asserted-by":"crossref","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines.","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"390_CR14","doi-asserted-by":"publisher","unstructured":"Gan L, Lyu X, Yang X, et al. Application of angiotensin receptor\u2013neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus. Front Med. 2022;9. https:\/\/doi.org\/10.3389\/fmed.2022.877237. Accessed 29 Feb 2024.","DOI":"10.3389\/fmed.2022.877237"},{"key":"390_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","volume":"3","author":"O Iborra-Egea","year":"2017","unstructured":"Iborra-Egea O, G\u00e1lvez-Mont\u00f3n C, Roura S, et al. Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017;3:12. https:\/\/doi.org\/10.1038\/s41540-017-0013-4.","journal-title":"NPJ Syst Biol Appl"},{"issue":"4","key":"390_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401\u201314. https:\/\/doi.org\/10.1177\/0091270009343932.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"390_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1310\/hpj5011-1025","volume":"50","author":"DJ Cada","year":"2015","unstructured":"Cada DJ, Baker DE, Leonard J. Sacubitril\/valsartan. Hosp Pharm. 2015;50(11):1025\u201336. https:\/\/doi.org\/10.1310\/hpj5011-1025.","journal-title":"Hosp Pharm"},{"issue":"30","key":"390_CR18","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","volume":"36","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015;36(30):1967\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehv142.","journal-title":"Eur Heart J"},{"key":"390_CR19","doi-asserted-by":"crossref","unstructured":"Efficacy and safety comparative of sacubitril\/valsartan vs. olmesartan in the treatment of hypertension: a meta-analysis of RCTs. Am J Hypertens. Oxford Academic. https:\/\/academic.oup.com\/ajh\/article\/36\/12\/643\/7246348. Accessed 29 Feb 2024.","DOI":"10.1093\/ajh\/hpad075"},{"issue":"1","key":"390_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","volume":"69","author":"TD Wang","year":"2017","unstructured":"Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69(1):32\u201341. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08484.","journal-title":"Hypertension"},{"issue":"17","key":"390_CR21","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"issue":"9851","key":"390_CR22","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(12)61227-6.","journal-title":"Lancet"},{"issue":"5","key":"390_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","volume":"45","author":"H Rakugi","year":"2022","unstructured":"Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45(5):824\u201333. https:\/\/doi.org\/10.1038\/s41440-021-00819-7.","journal-title":"Hypertens Res"},{"key":"390_CR24","unstructured":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(09)61966-8\/abstract. Accessed 29 Feb 2024."},{"issue":"8","key":"390_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027612","volume":"12","author":"K Kario","year":"2023","unstructured":"Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Twenty-four-hour blood pressure-lowering efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: a post hoc analysis of data from a randomized, double-blind multicenter study. J Am Heart Assoc. 2023;12(8): e027612. https:\/\/doi.org\/10.1161\/JAHA.122.027612.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"390_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"B Williams","year":"2017","unstructured":"Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension. Hypertension. 2017;69(3):411\u201320. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08556.","journal-title":"Hypertension"},{"key":"390_CR27","unstructured":"Cardiac remodeling in systemic hypertension\u2014Medical Clinics. https:\/\/www.medical.theclinics.com\/article\/S0025-7125(03)00168-8\/fulltext. Accessed 29 Feb 2024."},{"issue":"12","key":"390_CR28","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1113\/JP273043","volume":"595","author":"J Tomek","year":"2017","unstructured":"Tomek J, Bub G. Hypertension-induced remodelling: on the interactions of cardiac risk factors. J Physiol. 2017;595(12):4027\u201336. https:\/\/doi.org\/10.1113\/JP273043.","journal-title":"J Physiol"},{"issue":"44","key":"390_CR29","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","volume":"38","author":"RE Schmieder","year":"2017","unstructured":"Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308\u201317. https:\/\/doi.org\/10.1093\/eurheartj\/ehx525.","journal-title":"Eur Heart J"},{"issue":"3","key":"390_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/jch.14422","volume":"24","author":"B Wang","year":"2022","unstructured":"Wang B, Wang GH, Ding XX, et al. Effects of sacubitril\/valsartan on resistant hypertension and myocardial work in hemodialysis patients. J Clin Hypertens (Greenwich). 2022;24(3):300\u20138. https:\/\/doi.org\/10.1111\/jch.14422.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"390_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cardfail.2022.10.432","volume":"29","author":"G Gjyriqi","year":"2023","unstructured":"Gjyriqi G, York M, Abuazzam F, et al. Angiotensin receptor neprilysin inhibitor use and blood pressure lowering in patients with heart failure with reduced ejection fraction across the spectrum of kidney function: an analysis of the veterans administrative health system. J Card Fail. 2023;29(3):258\u201368. https:\/\/doi.org\/10.1016\/j.cardfail.2022.10.432.","journal-title":"J Card Fail"},{"issue":"5","key":"390_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LCY, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17(5):510\u20137. https:\/\/doi.org\/10.1002\/ejhf.232.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"390_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2022.10.033","volume":"81","author":"E Eworuke","year":"2023","unstructured":"Eworuke E, Welch EC, Haug N, et al. Comparative risk of angioedema with sacubitril-valsartan vs renin\u2013angiotensin\u2013aldosterone inhibitors. J Am Coll Cardiol. 2023;81(4):321\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.033.","journal-title":"J Am Coll Cardiol"},{"key":"390_CR34","unstructured":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study\u2014ScienceDirect. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0167527317378026. Accessed 18 Aug 2024."},{"issue":"18","key":"390_CR35","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.jacc.2021.03.291","volume":"77","author":"V Parcha","year":"2021","unstructured":"Parcha V, Patel N, Gutierrez OM, et al. Chronobiology of natriuretic peptides and blood pressure in lean and obese individuals. J Am Coll Cardiol. 2021;77(18):2291\u2013303. https:\/\/doi.org\/10.1016\/j.jacc.2021.03.291.","journal-title":"J Am Coll Cardiol"},{"key":"390_CR36","unstructured":"Wang JG. Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with amlodipine on ventricular remodeling in hypertension and left ventricular hypertrophy. clinicaltrials.gov. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04929600. Accessed 1 Jan 2024."},{"key":"390_CR37","unstructured":"Duraes AR. Anti-hypertensive effect of sacubitril\/valsartan in resistant hypertension: randomized clinical trial\u2014The HEVA Study. clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/study\/NCT04637152. Accessed 1 Jan 2024."},{"issue":"9","key":"390_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000507327","volume":"145","author":"Q Geng","year":"2020","unstructured":"Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (sacubitril\/valsartan) on blood pressure in patients with hypertension: a meta-analysis of randomized controlled trials. Cardiology. 2020;145(9):589\u201398. https:\/\/doi.org\/10.1159\/000507327.","journal-title":"Cardiology"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00390-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T17:07:15Z","timestamp":1732900035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00390-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00390-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"29 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Uday M. Jadhav, Saumitra Ray, T. Govindan Unni, J. P. S. Sawhney, Ashwani Mehta, Shantanu Guha, Rajiv D. Karnik, Bhupen N. Desai, Aziz Khan, Keyur Patel, Jayesh S.\u00a0Prajapati, Hitesh J. Shah, Rama Krishna Reddy, Sanjeev Kumar, Soumya Kanti Dutta, Saujatya Chakraborty, Ashfaque Ahmed, Ravi Vishnu Prasad, Gaurav Chaudhary, Amit Kumar, Manjappa M., Sujal Shetty, Praveen Raja, and Vimalraj Bonagna Shanmugam, have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All the experts consulted for this paper are listed as authors, and they have consented to their comments being published in a scientific journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}